

PUREfrex® : The Rebuilt Protein Factory




Takashi (Ebi) Ebihara, Ph.D.
COO
GeneFrontier Corporation

PepTalk 2026
19-22 of January, 2026



Corporate Summary



GeneFrontier

Founded: ***Oct 13th, 2010 (renewed)***

Shareholder: ***KANEKA Corporation (100%)***


People: ***17 (Ph.D. 8, MS 1)***

Place: ***Chiba, Japan***



Mission: ***Rebuilding and Manipulating Biological system
for Inspiring the world!***



**Only necessary molecules
for transcription/translation**




=Breaking down & Building up



PURE system

(Protein synthesis Using Recombinant Elements)

***Shimizu Y. et al. Nature Biotechnology
vol 19, p751–755 (2001)***




PURE system




Reconstituted cell-free protein synthesis kit



PUREfrex[®]

For Designing Central Dogma





FASTIA: Fast Interaction Analysis



**Membrane protein/
Difficult-to-express protein**

PURE system

Reconstituted cell-free protein synthesis kit

PUREfres

For Designing Central Dogma


Suitable for AI/ML approach

**Speedy & Scalable
& Reproducible
reaction**

Synthesized DHFR mg/mL


Ver. 1.0 Ver. 2.0/2.1

366.02 1000.986



Fujita et al. (2023) ACS Nano. vol.17(4), p.3358.

Sugii et al. (2023) Synth. Biol. vol.8, p1







et al. (2024) ACS Sens, 9(6):2846-2857.

Tsuboyama et al. (2023) Nature, 620, p434.


-Improve Validation from Weeks to Days-

FASTIA: Fast Interaction Analysis






[Matsunaga et al. \(2025\) Protein Sci. Mar;34\(3\):e70065. doi: 10.1002/pro.70065.](https://doi.org/10.1002/pro.70065)

-Expression of scFv, Fab, IgG and more-




Activity



[Murakami et al. \(2019\) Sci. Rep. vol.9, p.671. \(Supplementary Information\)](#)

[Murakami et al. \(2019\) Sci. Rep. vol.9, p.671.](#)



Round 1: IFN-α variants tested by in vitro transcription/translation


IFN-α variants were generated as IFNα-scFv fusions to identify mutations affecting activity in mouse and human cells

- Universal IFN-α
- hIFN_u_L152F
- R121K
- R121K_Q125R
- R121K_Q125R_K132T
- Y86C_R121K_Q125R
- Y86C_R121K_Q125R_K132T
- mIFN2
- IFN_u2b
- scFv control
- Human IFN_u2b (starts at 1nM)
- No DNA

IFN-α-scFv protein was generated with an anti-PDL1 antibody by in vitro transcription/translation using the PUREfres[®] system (CosmoBIO USA). Protein mixture was serially diluted and protein was captured via an anti-V5 tag coated to the wells of the plate. Proteins were assayed for PD-L1 binding to assess expression (data not shown) or the ability to stimulate an IFN-α response in receptor reporter cell lines

[Killebrew et al. \(2024\) SITC 2024 Annual Meeting \(Poster, BONUMTX.com\).](#)


-Application for complex molecule-



Jensen et al. (2021) *Protein Expr. Purif.*, 186, 105910.

	1	2	3	4	5	6	7	8	9	10
	Proinsulin Aspart	Proinsulin Lispro	Proinsulin Glargine	Regular Proinsulin	Insulin A Chain	Insulin B Chain	Insulin A Chain Heterodimer	Insulin B Chain Heterodimer	Oxytocin	Glucagon
PURE	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Clm24	✗	✗	✗	✗	✓	✗	✓	✓	✓	✓
BL21	✗	✗	✗	✗	✓	✗	✓	✓	✓	✗
759	✓	✓	✓	✓	✓	✓	✓	✓	✓	✗
	11	12	13	14	15	16	17	18	19	20
	Glucagon Like Peptide 1 mutant (GLP-1 mut)	Glucagon Like Peptide 1 (GLP-1)	Insulin Like Growth Factor	Growth Hormone (GH)	Leptin	Vaso-pressin	Angiotensin II	Parathyroid Hormone (PTH)	Somato-statin	Leuprolide
PURE	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Clm24	✓	✓	✗	✓	✓	✓	✓	✓	✓	✓
BL21	✗	✗	✗	✗	✗	✗	✓	✓	✓	✓
759	✓	✓	✗	✓	✓	✓	✓	✗	✓	✓


DeWinter et al. (2023) *ACS Synth. Biol.* vol.12, 4, p1216. (Supplementary Information)




Shayan et al. (2025) *New Biotechnology*, vol 89, p51.



In vitro expression and Biacore analysis of Fab fragments




Kinetic analysis of 25 Fab binders



→ Selection of Fabs for further kinetic analysis


EME Epsilon Molecular Engineering Molecular Design for Human Life



<https://www.epsilon-mol.co.jp/eng/>



iBody's Ecobody Technology



- Ecobody is...
- Human/Rabbit derived
 - mAb in "Only 2" days!
 - Fully in vitro screening
 - No culture


<https://www.ibody.co.jp/en/>

FUJIFILM peptide discovery services collaborated with PUREfres






- ✓ **Innovative improvements** in mRNA display enable screening from $>10^{13}$ peptides
 - ✓ **Practical biosynthesis & assays** enable rapid selection and activity explorations.
- Peptides hits with **wide varieties** and **high-affinities** can be obtained.

We provide a CRO service, in which we receive target (🧬) from the customer* and return the structural information of the acquired peptides (📄).

* Required target protein: 0.1~0.5 mg, >90% in purity




-Broad applications, yet to come!-




[Predenia et al. \(2025\) RSC Chem. Biol, 6\(1313\).](https://doi.org/10.1039/C5SC01313A)

[Grasemann et al. \(2025\) bioRxiv.
https://doi.org/10.1101/2025.09.23.678000.](https://doi.org/10.1101/2025.09.23.678000)

-Broad applications, yet to come!-




[Chui Z. et al. \(2024\) ACS Sens, 9\(6\):2846-2857.](#)




[Zimmermann I. et al. \(2018\) eLife, 7, e34317.](#)


in vitro protein selection technology
PUREfres[®] RD




Licensed technology under JP4931135 etc.




Licensed to
SUTRO BIOPHARMA




[Tsuboyama et al. \(2023\) Nature, 620, p434.](#)



[Wang et al. \(2025\) Acta Pharmaceutica Sinica B. vol.15\(5474\).](#)





-Broad applications, yet to come!-



[Pandi A et al. \(2022\) Nature Communications, 13, 3876.](#)


Round	3			4		5			6			
Composition No.	2	21	27	4	13	14	2	8	29	1	7	8
K Glutamate	Blue											
Mg Acetate	Blue											
Spermidine	Blue											
Creatine Phosphate	Blue											
ATP	Blue											
GTP	Blue											
CTP/UTP	Blue											
tRNA	Blue											
IF2	Red											
EF-G	Red											
EF-Tu/EF-Ts	Red											
T7 RNAP	Red											
Ribosome	Blue											



- ✓ Perfect fit to AI/ML approach with great controllability & reproducibility.
- ✓ Unique expression platform will give you great advantage in R&D.

-KSF; AT rich codon on N-term-


Fab Heavy Chain (Herceptin)



All clones; 384
Tested clones; 56

Frequency (Glu, Gln)	65%	50%	35%
Frequency (Val, Leu)	35%	25%	15%

*Frequency is calculated from Codon Usage Database in Kazusa DNA Res.Inst. (E. coli K-12 strain)



Design of DNA template is important.


Manual is free to download from our Web site here.



PD1

Organism: *Homo sapiens*
Synthesized region: 36Thr-150Glu(-Hisx8)
Length: 124 a.a.
Molecular weight: 14,148 Da


N-term type	1	2(36)	3(37)	4(38)	5(39)	6(40)	GC(%) 1-6 a.a.
Met	Thr	Phe	Ser	Pro	Ala		
GC	atg	acc	ttc	tcc	cgc	gcg	67%
Major	atg	acc	ttt	tct	cgc	gcg	56%
AT	atg	act	ttt	tca	cca	gct	39%



PDL1

Organism: *Homo sapiens*
Synthesized region: 18Ala-239Thr(-Hisx8)
Length: 231 a.a.
Molecular weight: 26,593 Da


N-term type	1	2(18)	3(19)	4(20)	5(21)	6(22)	GC(%) 1-6 a.a.
Met	Ala	Phe	Thr	Val	Thr		
GC	atg	gcg	ttc	acc	gtg	acc	61%
Major	atg	gcg	ttt	acc	gtg	acc	56%
AT	atg	gct	ttt	act	gta	aca	33%



Citrate Synthase

Organism: *Saccharomyces cerevisiae*
Synthesized region: 38Ser-479Asn
Length: 443 a.a.
Molecular weight: 49,346 Da


N-term type	1	2(38)	3(39)	4(40)	5(41)	6(42)	GC(%) 1-6 a.a.
Met	Ser	Ser	Ala	Ser	Glu		
GC	atg	tcc	tcc	gcg	tcc	gag	67%
Major	atg	tct	tct	gcg	tct	gaa	44%
AT	atg	tca	tca	gct	tca	gaa	39%



PTGDS

Organism: *Homo sapiens*
Synthesized region: 23Ala-190Gln
Length: 169 a.a.
Molecular weight: 18,829 Da


N-term type	1	2(23)	3(24)	4(25)	5(26)	6(27)	GC(%) 1-6 a.a.
Met	Ala	Pro	Glu	Ala	Gln		
GC	atg	gca	cgc	gaa	gca	cag	61%
Major	atg	gcg	cgc	gaa	gcg	cag	72%
AT	atg	gca	cct	gaa	gct	caa	50%



GM-CSF

Organism: *Homo sapiens*
Synthesized region: 18Ala-144Glu
Length: 128 a.a.
Molecular weight: 14,808 Da


N-term type	1	2(18)	3(19)	4(20)	5(21)	6(22)	GC(%) 1-6 a.a.
Met	Ala	Pro	Ala	Arg	Ser		
GC	atg	gcg	cgc	gcg	cgc	tcc	83%
Major	atg	gcg	cgc	gcg	cgc	tct	78%
AT	atg	gca	cct	gct	aga	tca	50%



His-α-Synuclein

Organism: *Homo sapiens*
Synthesized region: (Hisx6)-(Gly-Ser)-2(10)Asp-140(148)Ala
Length: 148 a.a.
Molecular weight: 15,427 Da

Tag type	1	2	3	4	5	6	7	8	9	GC(%) 1-9 a.a.
Met	His	Gly	Ser							
GC	atg	cac	ccc	cac	ccc	cac	cac	ggt	tct	59%
Major	atg	cct	cct	cct	cct	cct	cct	ggt	tct	37%



DNA design for PUREfres



Amino acid sequence entry form

Consultation is free of charge!

-KSF; Quality of DNA-

#	Construct	Size (bp)	Elegen's ENFINIA DNA	Supplier B	Supplier C
			Format	Format	Format
1	HisTEV-sfGFP(G4Y)-PPG-FLAG	978	Linear dsDNA	N/A	Linear dsDNA
2	HisTEV-PPG-sfGFP(G4Y)-FLAG	978	Linear dsDNA	N/A	Linear dsDNA
3	HisTEV-sfGFP(G4Y)-FLAG	888	Linear dsDNA	Linear dsDNA	Linear dsDNA
4	sfGFP(G4Y)-FLAG	840	Linear dsDNA	Linear dsDNA	Linear dsDNA







Figure 1. Analysis of DNA synthesized by three vendors. DNA synthesized by Elegen (Supplier A), Supplier B, and Supplier C was quantified using a Qubit Fluorometer (Thermo Fisher Scientific) and subjected to agarose gel electrophoresis.

Protein



To learn more about ENFINIA DNA, visit elegenbio.com or contact us at info@elegenbio.com


Contact information

Reconstituted cell-free protein synthesis kit

PUREfrefx[®]

*For reagent use for expression / screening of biologics
/designing central dogma*

<https://purefrefx.genefrontier.com/>



in vitro protein selection technology

PUREfrefx[®]RD

*For screening service / collaboration / technology transfer
for generation of new biologics*

Takashi Ebihara, Ph.D., COO, GeneFrontier

E-mail: ebihara@genefrontier.com



GMP VHH Antibody Manufacturing

We offer a robust VHH production platform, developed through extensive testing of diverse VHH models under a wide range of conditions:

- **mono-, bi-, and tri-specific** formats
- Isoelectric points between **pI 5 and 9**
- Diverse **hydrophobicity** properties



8 only Months

Starting from your research cell bank, we rapidly identify the optimal setup and process conditions to efficiently produce your VHH.

VHH Platform



Two expression platforms

- *P. pastoris* (*K. phaffii*)
- *E. coli*



Fermentation

- High-cell density fed-batch
- Control of critical fermentation parameters
- Animal-free media



Purification types

- Ion-Exchange
- Hydrophobic Interaction Chromatography (HIC)
- Mix mode
- Affinity



Quality control & release

- GMP QC package
- Additional custom QC development available
- QP release



Quick to clinic



Designed for Tox & PhI



GMP quality



End-to-End assistance